API China brought together more than 30,000 visitors and about 1,200 exhibitors from 12–14th November 2025 at the Chongqing International Expo Center, across 70,000 square meters of exhibition space.
RNA therapeutics represent one of the most promising frontiers in modern medicine, offering highly specific mechanisms of action and the potential to address previously undruggable diseases. Dave Butler, Hongene discusses.
Nanoform Finland, the medicine performance-enhancing company, has announced that it has received a Commercial cGMP Manufacturing License from FIMEA (Finnish Medicines Agency) for the production and quality control of nanoformed small molecule APIs.
Tom Moody, Jonathan Loughrey, Martin McCabe, Scott Wharry and Stephen Hughes, Almac Group, explores vertical integration of supply chains and technology integration in Active Pharmaceutical Ingredient (API) manufacture.
API China, Asia’s exhibition for pharmaceutical ingredients and manufacturing, will convene its 93rd edition at the Chongqing International Expo Center from 12–14 November 2025.
With the increasing prevalence of poorly soluble drugs in the pharmaceutical pipeline, Matt Finkelhor, commercial manager, Global Novel Polymers at Lubrizol, explores how to realise therapeutic potential with the right excipients.
Lubrizol will showcase the benefits of its polymer-based excipients for the solubility, bioavailability and palatability of APIs and nutraceuticals at CPHI Frankfurt (28th- 30th October 2025 at Stand 8.0M71).
